EP1131334A4 - Use of core 2 glcnac transferase inhibitors in treating inflammation - Google Patents

Use of core 2 glcnac transferase inhibitors in treating inflammation

Info

Publication number
EP1131334A4
EP1131334A4 EP99959043A EP99959043A EP1131334A4 EP 1131334 A4 EP1131334 A4 EP 1131334A4 EP 99959043 A EP99959043 A EP 99959043A EP 99959043 A EP99959043 A EP 99959043A EP 1131334 A4 EP1131334 A4 EP 1131334A4
Authority
EP
European Patent Office
Prior art keywords
core
treating inflammation
transferase inhibitors
glcnac transferase
glcnac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99959043A
Other languages
German (de)
French (fr)
Other versions
EP1131334A1 (en
Inventor
Jamey D Marth
Leslie G Ellies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of EP1131334A1 publication Critical patent/EP1131334A1/en
Publication of EP1131334A4 publication Critical patent/EP1131334A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
EP99959043A 1998-11-21 1999-11-20 Use of core 2 glcnac transferase inhibitors in treating inflammation Withdrawn EP1131334A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10941698P 1998-11-21 1998-11-21
US109416P 1998-11-21
US11367998P 1998-12-21 1998-12-21
US113679P 1998-12-21
PCT/US1999/027465 WO2000031109A1 (en) 1998-11-21 1999-11-20 USE OF CORE 2 GlcNAc TRANSFERASE INHIBITORS IN TREATING INFLAMMATION

Publications (2)

Publication Number Publication Date
EP1131334A1 EP1131334A1 (en) 2001-09-12
EP1131334A4 true EP1131334A4 (en) 2003-05-21

Family

ID=26806952

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99959043A Withdrawn EP1131334A4 (en) 1998-11-21 1999-11-20 Use of core 2 glcnac transferase inhibitors in treating inflammation

Country Status (5)

Country Link
EP (1) EP1131334A4 (en)
JP (1) JP2002530425A (en)
AU (1) AU1629700A (en)
CA (1) CA2347940A1 (en)
WO (1) WO2000031109A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4599027B2 (en) * 2002-10-30 2010-12-15 東洋水産株式会社 L-selectin binding inhibitor
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006176A2 (en) * 1995-08-03 1997-02-20 Board Of Regents Of The University Of Oklahoma Peptide and o-glycan inhibitors of selectin mediated inflammation
CA2186987A1 (en) * 1996-10-02 1998-04-02 George L. King Inhibitors of core 2 glcnac-t and use of the inhibitors to prevent or treat cardiomyopathy associated with diabetes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5461143A (en) * 1991-03-18 1995-10-24 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
US5360733A (en) * 1992-10-01 1994-11-01 La Jolla Cancer Research Foundation Human β1-6 n-acetylglucosaminyl transferase
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006176A2 (en) * 1995-08-03 1997-02-20 Board Of Regents Of The University Of Oklahoma Peptide and o-glycan inhibitors of selectin mediated inflammation
CA2186987A1 (en) * 1996-10-02 1998-04-02 George L. King Inhibitors of core 2 glcnac-t and use of the inhibitors to prevent or treat cardiomyopathy associated with diabetes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ELLIES, LESLEY G. ET AL: "Core 2 oligosaccharide biosynthesis distinguishes between selectin ligands essential for leukocyte homing and inflammation", IMMUNITY (1998), 9(6), 881-890, XP002235083 *
HINDSGAUL, OLE ET AL: "Evaluation of deoxygenated oligosaccharide acceptor analogs as specific inhibitors of glycosyltransferases", JOURNAL OF BIOLOGICAL CHEMISTRY (1991), 266(27), 17858-62, XP000999205 *
JAIN, RAKESH K. ET AL: "Inhibition of L- and P- selectin by a rationally synthesized novel core 2 -like branched structure containing GalNAc-Lewisx and Neu5Ac.alpha.2-3Gal.beta.1-3GalNAc sequences", GLYCOBIOLOGY (1998), 8(7), 707-717, XP001011268 *
MAAHEIMO, HANNU ET AL: "Synthesis of a divalent sialyl Lewis x O-glycan, a potent inhibitor of lymphocyte-endothelium adhesion. Evidence that multivalency enhances the saccharide binding to L-selectin", EUROPEAN JOURNAL OF BIOCHEMISTRY (1995), 234(2), 616-25, XP000613069 *
See also references of WO0031109A1 *

Also Published As

Publication number Publication date
JP2002530425A (en) 2002-09-17
CA2347940A1 (en) 2000-06-02
WO2000031109A1 (en) 2000-06-02
AU1629700A (en) 2000-06-13
EP1131334A1 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
HUP0101809A3 (en) Inhibitors of type 5 and type 3 17betha-hydroxysteroid dehydrogenase and methods for their use
EP0755383A4 (en) Inhibitors of farnesyl-protein transferase
HU9602516D0 (en) Isoprenyl transferase inhibitors
EP0784473A4 (en) Inhibitors of farnesyl-protein transferase
EP0891350A4 (en) Inhibitors of farnesyl-protein transferase
EP1011669A4 (en) Inhibitors of farnesyl-protein transferase
EP0777475A4 (en) Inhibitors of farnesyl-protein transferase
IL138906A0 (en) Quinolones used as mrs inhibitors and bactericides
GB9604311D0 (en) Inhibitors of farnesyl-protein transferase
EP0783318A4 (en) Inhibitors of farnesyl-protein transferase
EP0904080A4 (en) Inhibitors of farnesyl-protein transferase
EP0880320A4 (en) Inhibitors of farnesyl-protein transferase
EP0783305A4 (en) Inhibitors of farnesyl-protein transferase
EP0891349A4 (en) Inhibitors of farnesyl-protein transferase
EP0812203A4 (en) Inhibitors of geranylgeranyl-protein transferase
IL115471A0 (en) Inhibitors of farnesyl-protein transferase and their use
EP0760813A4 (en) Inhibitors of farnesyl-protein transferase
EP0891352A4 (en) Inhibitors of farnesyl-protein transferase
EP1131334A4 (en) Use of core 2 glcnac transferase inhibitors in treating inflammation
GB9506174D0 (en) Inhibitors of farnesyl-protein transferase
EP0891335A4 (en) Inhibitors of farnesyl-protein transferase
EP0891353A4 (en) Inhibitors of farnesyl-protein transferase
EP0787123A4 (en) Inhibitors of farnesyl-protein transferase
EP0959883A4 (en) Inhibitors of farnesyl-protein transferase
EP0877610A4 (en) Inhibitors of farnesyl-protein transferase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010619

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12Q 1/48 B

Ipc: 7C 12N 15/11 B

Ipc: 7A 61K 48/00 B

Ipc: 7C 12N 15/85 B

Ipc: 7C 12N 15/63 B

Ipc: 7C 07K 16/00 B

Ipc: 7C 07H 21/04 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030403

17Q First examination report despatched

Effective date: 20070914

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080326